Hoppa till innehåll

Sanofi-aventis annonser första patient utanför USA fick behandling med Kevzara® (sarilumab)

Phase 2/3 trial initiated in Italy, Spain, Germany, France, Canada and Russia and is enrolling patients immediately
Kevzara inhibits IL-6, which may play a role in driving the inflammatory immune response that causes acute respiratory distress syndrome observed in patients with severe COVID-19 infection
Sanofi is leading trials outside the U.S., while Regeneron is leading U.S. trials

Kevzara is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor. IL-6 may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or critically ill with COVID-19 infection. The role of IL-6 is supported by preliminary data from a single-arm study in China using another IL-6 receptor inhibitor

Läs mer Sanofi

NCT04315298

Kevzara är används mot svårt reumatoid artrit som en enda terapi eller tillsammans med MTX

Publicerat iCovid-19 och reumatiska sjukdomar